Hyperfine, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Financial amounts below are in U.S. dollars; figures are shown in millions unless otherwise noted. Hyperfine develops and sells the Swoop portable, ultra-low-field brain MRI system and related services. Its Liminal brain-sensing program was suspended in December 2022.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $2.33 | $2.35 | $8.35 | $5.39 |
| Gross profit | $1.12 | $0.69 | $3.72 | $0.61 |
| Gross margin | 48.2% | 29.3% | 44.6% | 11.3% |
| Operating expenses | $12.88 | $13.97 | $40.21 | $60.85 |
| Operating loss | $(11.76) | $(13.28) | $(36.49) | $(60.25) |
| Net loss | $(10.76) | $(13.17) | $(33.55) | $(60.11) |
| Net loss per share, basic and diluted | $(0.15) | $(0.19) | $(0.47) | $(0.85) |
- Revenue mix: Q3 device sales were $1.73 million, down 11.2%, while service revenue rose 49.4% to $0.60 million. For the nine months, device and service revenue grew 54.9% and 54.5%, respectively.
- Cash flow: Operating cash used was $31.87 million for the first nine months, versus $56.99 million in 2022. Investing used $0.55 million; financing provided $0.15 million. Cash, cash equivalents and restricted cash declined $32.27 million to $85.97 million, including $85.42 million unrestricted cash.
- Liquidity and debt: Current assets were $98.22 million and current liabilities $8.21 million at September 30. The filing reports no debt balance. Management expects existing cash and product/service proceeds to fund planned operations for at least 12 months, while cautioning that additional capital may be needed if circumstances change.
- Other balance-sheet facts: Inventory rose to $6.94 million from $4.62 million at year-end 2022. Total liabilities were $9.30 million and stockholders’ equity was $93.77 million.
Material changes versus prior comparable periods
- Q3 revenue was nearly flat year over year: device revenue fell on lower unit volume, partly offset by higher selling price; service revenue increased with the installed commercial base. Nine-month revenue rose 54.8%.
- Gross margin improved in both comparisons, supported by lower device cost of sales and, in Q3, lower service costs.
- Nine-month operating expenses fell 33.9%, primarily with lower personnel, stock-based compensation, consulting, sales and marketing costs following the 2022 restructuring and reduced headcount. Q3 G&A increased 44.3%, largely because the 2022 comparison included a stock-based compensation credit for forfeited former-CEO awards.
- Higher interest income ($2.92 million for nine months versus $0.20 million) partly reflected higher rates and cash balances, helping reduce the net loss.
- The installed base reached 133 systems, up from 100 a year earlier, including 91 commercial units versus 57. The filing identifies 21 research units and 21 grant-fulfillment units at September 30, 2023.
Outlook, management commentary, risks and unusual items
- Management plans continued product and software development, commercial expansion and investment in sales and support, while expecting significant cash burn and recurring net losses until gross profit covers operating expenses. No specific revenue, earnings or margin guidance is provided.
- FDA clearances in February and October 2023 covered Swoop software updates, including improved diffusion-weighted imaging and AI-based denoising. The company also cites marketing authorizations in several other countries.
- A May 2023 Bill & Melinda Gates Foundation grant of $3.35 million supports work on neurodevelopment measurement using low-field MRI through February 2026; $0.50 million had been received by September 30. Grant funds are restricted to project purposes and unused funds may have to be returned. The filing also reports an extension of an earlier grant agreement to February 2024.
- Key risks include reliance on a single-source manufacturer and suppliers, uncertain adoption and commercialization, continued losses and possible future financing needs, inflation and manufacturing costs, and competition. Management says it cannot assure profitability or that capital will be available on acceptable terms.
- The company reported no material litigation, no material changes to previously disclosed risk factors, and no probable litigation loss requiring accrual. Purchase commitments are primarily due within one year and generally may be adjusted or cancelled under their terms.
- Former CEO Khan Siddiqui’s separation agreement was dated September 30, 2023, with a consulting agreement also disclosed. The filing does not provide the financial terms in the supplied text. The company recorded no liability for a potential $1.0 million service-provider payment tied to earn-out shares because the earn-out criteria had not been met.
Important facts for investors to verify
- Whether commercial device demand and service revenue growth continue, particularly given Q3 device sales declined year over year.
- Cash consumption relative to the stated minimum 12-month operating runway, and whether additional financing will be required.
- Inventory levels, supply continuity with the single-source manufacturer, and the conversion of inventory and installed systems into paid sales.
- Progress on Gates Foundation milestones, restricted grant cash, and the timing and economics of grant-supported deployments.
- Management transition details and any associated separation, consulting or equity-compensation costs; also assess potential dilution from outstanding options, RSUs and earn-out shares.